CTLA4 and hepatocellular carcinoma: Another consideration is whether allogeneic or autologous FMT should be employed, especially since current FDA-approved immunotherapies, such as anti-PD-1 or anti-CTLA4, have limited efficacy only for a small fraction of HCC patients (10–25% range undergoing monotherapy).